The effectiveness of SPRAVATO ® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. 1 SPRAVATO ® is the first and only approved medicine that has been shown to reduce depressive symptoms within 24 hours, 1 providing a new option for significant symptom relief until a longer-term, comprehensive treatment plan can take effect. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for SPRAVATO ® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation orbehavior. – (August 3, 2020) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S.
0 Comments
Leave a Reply. |